GSK Investigational Site

New Lambton, New South Wales 2310

0 studies enrolling now · 10 studies all time

What they study most

Asthma, Glomerulonephritis, Membranous, Pulmonary Disease, Chronic Obstructive, Vasculitis

Studies at this site

• Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level — Completed
• MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects — Completed
• Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients — Completed
• A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects — Completed
• Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma — Completed
• A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects — Completed
• Belimumab in Remission of VASculitis — Completed
• Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma — Completed
• Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma — Completed
• Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy — Withdrawn before enrolling